New Insights on the Treatment of Emotional Problems

  • Ángel José Martín Gargiulo
  • Paula José Quintero
  • Nicolás Cristi
  • Augusto Pascual ítalo Gargiulo


Suffering is part of having a valuable life, and emotions and thoughts are, in many cases, the cause of that suffering. The problem does not seem to be suffering itself but the context in which we live, a context that determines that suffering is not normal, leading to a psychological phenomenon called the experiential avoidance. At first, psychotherapies, following the predominant medicine paradigm, tend to search the way to reduce suffering. Today, they are emphasizing the necessity to focus on having values and tend to them, accepting emotions and relating with thoughts in different ways rather than treating them as symptoms to diminish. At the same time, there is strong evidence that shows that chronic exposure to stress has deleterious effects over different structures of the brain, resulting in different psychiatric clinical disorders. At the moment of conceptualizing the problems, clinicians might feel confused by the different approaches to understand emotions and may not know what to do in each case, debating between calming down the situation against letting the emotion do what it is supposed to. Frequently benzodiazepines and other drugs might be misused in this context. The purpose of this article is to review the literature around these facts to achieve a dialectic balance between letting suffer when it is expectable and medicating and/or soothing when it is necessary.


Emotions Dysregulation Stress Suffering Context Benzodiazepines Psychotherapies DBT 


  1. 1.
    Wegner DM, Schneider DJ, Carter SR 3rd, White TL. Paradoxical effects of thought suppression. J Pers Soc Psychol. 1987;53(1):5–13.PubMedCrossRefGoogle Scholar
  2. 2.
    Gibbs RW. Why irony sometimes comes to mind paradoxical effects of thought suppression. Pragmat Cogn. 2007;15(2):229–5.CrossRefGoogle Scholar
  3. 3.
    Rassin E, Merckelbach H, Muris P. Paradoxical and less paradoxical effects of thought suppression: a critical review. Clin Psychol Rev. 2000;20(8):973–95.PubMedCrossRefGoogle Scholar
  4. 4.
    Abramowitz JS, Tolin DF, Street GP. Paradoxical effects of thought suppression: a meta-analysis of controlled studies. Clin Psychol Rev. 2001;21(5):683–703.PubMedCrossRefGoogle Scholar
  5. 5.
    Giuliano RJ, Wicha NYY. Why the white bear is still there: electrophysiological evidence for ironic semantic activation during thought suppression. Brain Res. 2010;1316:62–74.PubMedCrossRefGoogle Scholar
  6. 6.
    Hayes SC, Strosahl KD, Wilson KG. Acceptance and commitment therapy. New York: The Guildford press; 1999.Google Scholar
  7. 7.
    Linehan M. Cognitive behavioral treatment of borderline personality disorder. New York: Guilford; 1993.Google Scholar
  8. 8.
    Kuhn T. ¿Qué son las revoluciones científicas?, y otros ensayos. Barcelona: Paidos; 1989.Google Scholar
  9. 9.
    Hayes SC. Acceptance and commitment therapy, relational frame theory, and the third wave of behavioral and cognitive therapies – republished article. Behav Ther. 2016;47:869–85.PubMedCrossRefGoogle Scholar
  10. 10.
    Jacobson NS, Dobson KS, Truax PA, Addis ME, Koerner K, Gollan JK, et al. SPECIAL FEATURE a component analysis of cognitive-behavioral treatment for depression. J Consult Clin Psychol. 1996;64(2):295–304.PubMedCrossRefGoogle Scholar
  11. 11.
    Longmore RJ, Worrell M. Do we need to challenge thoughts in cognitive behavior therapy? Clin Psychol Rev. 2007;27(2):173–87.PubMedCrossRefGoogle Scholar
  12. 12.
    Ilardi SS, Craighead WE. The role of nonspecific factors in cognitive-behavioral therapy for depression. Clin Psychol Sci Pract. 1994;59:12–9.Google Scholar
  13. 13.
    Craske MG, Kircanski K, Zelikowsky M, Mystkowski J, Chowdhury N, Baker A. Optimizing inhibitory learning during exposure therapy. Behav Res Ther. 2008;46(1):5–27.PubMedCrossRefGoogle Scholar
  14. 14.
    Bandelow B, Reitt M, Rover C, Michaelis S, Gorlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015;30(4):183–92.PubMedCrossRefGoogle Scholar
  15. 15.
    Kaczkurkin AN, Foa EB. Cognitive-behavioral therapy for anxiety disorders: an update on the empirical evidence. Dialogues Clin Neurosci. 2015;17(3):337–46.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Eifert GH, Forsyth JP. Acceptance and commitment therapy for anxiety disorders: a practitioner’s treatment guide to using mindfulness, acceptance, and values-based behavior change strategies. Oakland: New Harbinger Publications; 2005.Google Scholar
  17. 17.
    Frances A. Saving normal. New York: HarperCollins Publishers; 2013.Google Scholar
  18. 18.
    Pepper SC. World hypotheses: a study in evidence. Berkeley: University of California Press; 1942.Google Scholar
  19. 19.
    Hayes SC, Hayes LJ, Reese HW. Finding the philosophical core: a review of Stephen C. Pepper’s world hypotheses: a study in evidence. J Exp Anal Behav. 1988;50(1):97–111.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Hayes SC, Hayes LJ. Some clinical implications of contextualistic behaviorism: the example of cognition. Behav Ther. 1992;23(2):225–49.CrossRefGoogle Scholar
  21. 21.
    Linehan M. DBT skills training manual. 2nd ed. New York: The Guilford Press; 2015.Google Scholar
  22. 22.
    LeDoux J. Rethinking the emotional brain. Neuron [Internet]. 2012 [cited 2013 Nov 11]; 73(4):653–676. Available from:
  23. 23.
    Ledoux JE, Place W, York N, Kline N. Evolution of human emotion: a view through fear. Prog Brain Res. 2013;195:431–42.CrossRefGoogle Scholar
  24. 24.
    Lieb K, Zanarini MC, Schmahl C, Linehan MM, Bohus M. Borderline personality disorder. Lancet [Internet]. 2004;364(9432):453–61. Available from: CrossRefGoogle Scholar
  25. 25.
    Barlow DH, Farchione TJ, Fairholme CP, Ellard KK, Boisseau CL, Allen LB. Unified protocol for transdiagnostic treatment of emotional disorders. New York: Oxford University Press; 2010.CrossRefGoogle Scholar
  26. 26.
    Farchione TJ, Ellard KK, Boisseau CL, Thompson-Hollands J, Carl JR, Gallagher MW. Unified protocol for transdiagnostic treatment of emotional disorders: a randomized controlled trial. Behav Ther. 2012;43:666–78.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Griffin CE, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J [Internet]. 2013;13(2):214–23. Available from:
  28. 28.
    Koek RJ, Schwartz HN, Scully S, Langevin J-P, Spangler S, Korotinsky A, et al. Treatment-refractory posttraumatic stress disorder (TRPTSD): a review and framework for the future. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;70:170–218.CrossRefGoogle Scholar
  29. 29.
    Jeffreys M, Capehart B, Friedman MJ. Pharmacotherapy for posttraumatic stress disorder: review with clinical applications. J Rehabil Res Dev. 2012;49(5):703–15.PubMedCrossRefGoogle Scholar
  30. 30.
    el-Guebaly N, Sareen J, Stein MB. Are there guidelines for the responsible prescription of benzodiazepines? Can J Psychiatr. 2010;55(11):709–14.CrossRefGoogle Scholar
  31. 31.
    Lader M. Benzodiazepines revisited – will we ever learn? Addiction. 2011;106(12):2086–109.PubMedCrossRefGoogle Scholar
  32. 32.
    von Knorring L, Thelander S, Pettersson A. Treatment of anxiety syndrome. A systematic literature review. Summary and conclusions by the SBU. Lakartidningen. 2005;102(47):35. (47):3561–2, 3565–6, 3569Google Scholar
  33. 33.
    National Institute for Health and Care Excellence. Gener generalised anxiety disorder and panic alised anxiety disorder and panic disorder in adults: management disorder in adults: management clinical guideline Y Your responsibility our responsibility. 2011;(January 2011).Google Scholar
  34. 34.
    Hoffman EJ, Mathew SJ. Anxiety disorders: a comprehensive review of pharmacotherapies. Mt Sinai J Med. 2008;75(3):248–62.PubMedCrossRefGoogle Scholar
  35. 35.
    Puetz TW, Youngstedt SD, Herring MP. Effects of pharmacotherapy on combat-related PTSD, anxiety, and depression: a systematic review and Meta-regression analysis. PLoS One. 2015;10(5):e0126529.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Sin J, Spain D, Furuta M, Murrells T, Norman I. Psychological interventions for post-traumatic stress disorder (PTSD) in people with severe mental illness. Cochrane Database Syst Rev. 2017;1:CD011464.PubMedGoogle Scholar
  37. 37.
    van Minnen A, Arntz A, Keijsers GPJ. Prolonged exposure in patients with chronic PTSD: predictors of treatment outcome and dropout. Behav Res Ther. 2002;40(4):439–57.PubMedCrossRefGoogle Scholar
  38. 38.
    Berger W, Mendlowicz MV, Marques-Portella C, Kinrys G, Fontenelle LF, Marmar CR, et al. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review. Prog Neuro-Psychopharmacol Biol Psychiatry. 2009;33(2):169–80.CrossRefGoogle Scholar
  39. 39.
    Ipser JC, Stein DJ. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). Int J Neuropsychopharmacol. 2012;15(6):825–40.PubMedCrossRefGoogle Scholar
  40. 40.
    Herbert J, Goodyer IM, Grossman a B, Hastings MH, de Kloet ER, Lightman SL, et al. Do corticosteroids damage the brain? J Neuroendocrinol [Internet]. 2006 [cited 2013 Nov 2];18(6):393–411. Available from:
  41. 41.
    Gargiulo PA, Donoso AO. Distinct grooming patterns induced by intracerebroventricular injection of CRH, TRH and LHRH in male rats. Braz J Med Biol Res. 1996;29:375–9.PubMedGoogle Scholar
  42. 42.
    Llano López LH, Caif F, García S, Fraile M, Landa AI, Baiardi G, Lafuente JV, Braszko JJ, Bregonzio CGP. Anxiolytic-like effect of losartan injected into amygdala of the acutely stressed rats. Pharmacol Rep. 2012;64(1):54–63.PubMedCrossRefGoogle Scholar
  43. 43.
    Marinzalda M de los A, Perez PA, Gargiulo PA, Casarsa BS, Bregonzio C, Baiardi G. Fear-potentiated behaviour is modulated by central amygdala angiotensin II AT1 receptors stimulation. Biomed Res Int. 2014;2014:183248CrossRefGoogle Scholar
  44. 44.
    Lupien SJ, McEwen BS, Gunnar MR, Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci [Internet]. 2009 [cited 2013 Oct 31];10(6):434–445. Available from: PubMedCrossRefGoogle Scholar
  45. 45.
    Hedegaard M, Henriksen TB, Sabroe S, Secher NJ. Psychological distress in pregnancy and preterm delivery. BMJ. 1993;307:234–9.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Epidemiol Rev. 1995;17:165–71.PubMedCrossRefGoogle Scholar
  47. 47.
    O’Connor TG, et al. Prenatal anxiety predicts individual differences in cortisol in pre-adolescent children. Biol Psychiatry. 2005;58:211–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Glover V. Maternal stress or anxiety in pregnancy and emotional development of the child. Br J Psychiatry. 1997;171:105–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Buss C, et al. Maternal care modulates the relationship between prenatal risk and hippocampal volume in women but not in men. J Neurosci. 2007;27:2592–5.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Evans GW, English K. The environment of poverty: multiple stressor exposure, psychophysiological stress, and socioemotional adjustment. Child Dev. 2002;73:1238–48.PubMedCrossRefGoogle Scholar
  51. 51.
    Halligan SL, Herbert J, Goodyer I, Murray L. Disturbances in morning cortisol secretion in association with maternal postnatal depression predict subsequent depressive symptomatology in adolescents. Biol Psychiatry. 2007;62:40–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Cohen RA, et al. Early life stress and morphometry of the adult anterior cingulate cortex and caudate nuclei. Biol Psychiatry. 2006;59:975–82.PubMedCrossRefGoogle Scholar
  53. 53.
    Lupien SJ. Stress hormones and human memory function across the lifespan. Psychoneuroendocrinology. 2005;30:225–42.PubMedCrossRefGoogle Scholar
  54. 54.
    Pruessner JC. Self-esteem, locus of control, hippocampal volume, and cortisol regulation in young and old adulthood. NeuroImage. 2005;28:815–26.PubMedCrossRefGoogle Scholar
  55. 55.
    Heim C. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA. 2000;284:592–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Smith ME. Bilateral hippocampal volume reduction in adults with post-traumatic stress disorder: a meta- analysis of structural MRI studies. Hippocampus. 2005;14:798–807.CrossRefGoogle Scholar
  57. 57.
    Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry. 2004;161:1957–66.PubMedCrossRefGoogle Scholar
  58. 58.
    Sapolsky RM, Krey LC, McEwen BS. The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endocr Rev. 1986;7:284–301.PubMedCrossRefGoogle Scholar
  59. 59.
    Charney DS, Manji HK. Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE. 2004;2004(225):re5.PubMedGoogle Scholar
  60. 60.
    Gilbertson MW. Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma. Nat Neurosci. 2002;5:1242–7.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Magarinos A, Orchinik M, McEwen B. Morphological changes in the hippocampal CA3 region induced by non-invasive glucocorticoid administration: a paradox. Brain Res. 1998;809:314–8.PubMedCrossRefGoogle Scholar
  62. 62.
    McKittrick C, Magarinos A, Blanchard D, Blanchard R, McEwen B, Sakai R. Chronic social stress reduces dendritic arbors in CA3 of hippocampus and decreases binding to serotonin transporter sites. Synapse. 2000;36:85–94.PubMedCrossRefGoogle Scholar
  63. 63.
    Sapolsky R. Glucocorticoid toxicity in the hippocampus. Temporal aspects of synergy with kainic acid. Neuroendocrinology. 1986;43:440–4.PubMedCrossRefGoogle Scholar
  64. 64.
    Tombaugh G, Sapolsky R. Corticosterone accelerates hypoxia- and cyanide-induced ATP loss in cultured hippocampal astrocytes. Brain Res. 1992;588:154–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Maheu F, Joober R, Beaulieu S, Lupien S. Differential effects of adrenergic and corticosteroid hormonal systems on human short- and long-term declarative memory for emotionally arousing material. Behav Neurosci. 2004;118:420–8.PubMedCrossRefGoogle Scholar
  66. 66.
    De Kloet E. Brain corticosteroid balance and homeostatic control. Front Neuroendocrinol. 1991;12(4):95–16.Google Scholar
  67. 67.
    Hayashi R, Wada H, Ito KAI. Effects of glucocorticoids on gene transcription. Eur J Pharmacol. 2004;500:51–62.PubMedCrossRefGoogle Scholar
  68. 68.
    Stromberg J, Backstrom T, Lundgren P. Rapid non-genomic effect of glucocorticoid metabolites and neurosteroids on the gam- ma-aminobutyric acid-A receptor. Eur J Neurosci. 2005;21:2083–5.PubMedCrossRefGoogle Scholar
  69. 69.
    Vinkers C, Kalafateli AL, Rutten B, Kas M, Kaminsky Z, Turner J, et al. Traumatic stress and human DNA methylation: a critical review. Epigenomics. 2015;7(4):593–608.PubMedCrossRefGoogle Scholar
  70. 70.
    Yehuda R, Ph D, Bierer LM, Mitropoulou V, New AS, Schmeidler J, et al. The relationship of borderline personality disorder to posttraumatic stress disorder and traumatic events. Am J Psychiatry. 2003;160:2018–24.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Ángel José Martín Gargiulo
    • 1
    • 2
    • 3
  • Paula José Quintero
    • 1
    • 4
  • Nicolás Cristi
    • 2
  • Augusto Pascual ítalo Gargiulo
    • 5
  1. 1.Fundación ForoBuenos AiresArgentina
  2. 2.Centro de EpilepsiaHospital Ramos MejíaBuenos AiresArgentina
  3. 3.School of MedicineUniversidad AustralBuenos AiresArgentina
  4. 4.University of FloresBuenos AiresArgentina
  5. 5.Laboratory of Neurosciences and Experimental Psychology, Area of Pharmacology, Department of Pathology, Faculty of Medical SciencesNational University of CuyoMendozaArgentina

Personalised recommendations